Summary
Moderna has filed to raise $500 million in a very large biopharma IPO.
The firm is advancing a large pipeline of mRNA-based treatments for a wide variety of diseases.
MRNA has major collaboration partners and an ambitious approach where previous mRNA-based treatments have failed.
I'll provide an update when we learn more details about the IPO from management.
This idea was discussed in more depth with members of my private investing community, IPO Edge. Start your free trial today »

Quick Take
Moderna (MRNA) intends to raise gross proceeds of $500 million from a U.S. IPO, according to an S-1 registration statement.
The firm is developing mRNA-based technologies and treatments for a wide range of diseases.
MRNA is seeking to go public at a challenging time for biopharma firms due to stock market volatility.
When we learn more about the IPO, I’ll provide an update.

